I am a molecular epidemiologist, studying the environmental and genetic causes of cancer, particularly endometrial and breast cancer. I am studying the molecular markers that act as signatures for the environmental and-or genetic aetiology of a given canc
A number of previous studies have shown high levels of two proteins, STC1 and STC2, in a substantial subset of breast cancers. We are proposing to do the first definitive analyses of whether these hormone-like proteins contribute to breast cancer growth. If yes, they are suitable targets for development of new treatments.
Developing Microenvironment-based Prognostic Biomarkers For Early Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$132,743.00
Summary
Approximately 20% of breast cancer patients are now diagnosed with ductal carcinoma in situ (DCIS), an early stage where tumour cells are confined within the ducts of the breast and pose no threat to life. Once cells spread beyond the duct into surrounding breast tissue, risk of spread increases dramatically. This project aims to use a unique set of patient samples to identify markers that predict DCIS patients that are most at risk of spread, to personalise therapy to and reduce over-treatment.
Use Of Circulating Tumour DNA To Characterise The Mutational Landscape Of Marginal Zone Lymphoma, Monitor Treatment Response And Detect Emergence Of Resistance
Funder
National Health and Medical Research Council
Funding Amount
$128,224.00
Summary
Marginal zone lymphoma (MZL) is a subtype of B-cell non-Hodgkin lymphoma for which the molecular drivers of disease are poorly understood. We hypothesise that circulating tumour DNA may be ideal for characterising the genetic mutations that underpin MZL, monitoring treatment response and detecting emergence of resistance. This non-invasive method of disease monitoring has the potential to transform management of cancers such as MZL, identify new treatment options and improve survival outcomes.
It has been proposed that inflammation plays a major role in prostate cancer risk. We are well placed to test this hypothesis following up evidence from our MCCS and RFPCS studies of associations between inflammatory markers and prostate cancer risk. This proposed project may open for the first time opportunities for the prevention of prostate cancer.
Integrating Wnt-Apc Pathway With TGF-beta Signalling In Colon Cancer
Funder
National Health and Medical Research Council
Funding Amount
$342,364.00
Summary
Colon cancer is one of the leading causes of death of all cancers. Two molecular pathways have been independently implicated in colon cancer development. Emerging evidences suggest that the two pathways may work together in the colon polypus formation. This application will integrate two separate molecular causes to form a new coherent understanding of cancer development and offer new directions in development of novel colon cancer treatment.
Circulating Tumour DNA As A Personalized Biomarker In ER Positive Metastatic Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$124,676.00
Summary
This PhD aims to study the use of liquid biopsies for disease monitoring in metastatic estrogen receptor positive breast cancer. Liquid biopsies involve looking for circulating cancer-specific genetic material in the blood stream. Through the use of liquid biopsies, we hope to understand genetic differences and heterogeneity within metastatic breast cancer; identify potential therapeutic targets; and examine the mechanisms of treatment resistance to facilitate personalised cancer therapy.
Molecular Characterisation Of Early Precursor Lesions Of A Novel Ñserrated Pathwayî Of Colorectal Cancer Using Gene Expression And Proteomics.
Funder
National Health and Medical Research Council
Funding Amount
$318,338.00
Summary
In Australia, CRC is the second highest cause of all cancer-related deaths. If detected early, CRC has a high success rate of cure, but a percentage of precursor lesions escape detection and show aggressive clinical behaviour to progress to CRC. These are difficult to diagnosis with existing technologies. We aim to understand the biology behind sessile serrated adenoma pathways and hence enhance early detection, diagnosis and treatments strategies.